- Home
- GRX vs IFRX Comparison
GRX vs IFRX Comparison
Compare GRX & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- IFRX
- Stock Information
- Founded
- GRX 2007
- IFRX 2007
- Country
- GRX United States
- IFRX Germany
- Employees
- GRX N/A
- IFRX N/A
- Industry
- GRX Finance/Investors Services
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- IFRX Health Care
- Exchange
- GRX Nasdaq
- IFRX Nasdaq
- Market Cap
- GRX 160.2M
- IFRX 117.8M
- IPO Year
- GRX N/A
- IFRX 2017
- Fundamental
- Price
- GRX $9.89
- IFRX $1.15
- Analyst Decision
- GRX
- IFRX Strong Buy
- Analyst Count
- GRX 0
- IFRX 1
- Target Price
- GRX N/A
- IFRX $8.00
- AVG Volume (30 Days)
- GRX 39.7K
- IFRX 623.9K
- Earning Date
- GRX 01-01-0001
- IFRX 05-07-2025
- Dividend Yield
- GRX 5.98%
- IFRX N/A
- EPS Growth
- GRX N/A
- IFRX N/A
- EPS
- GRX 0.26
- IFRX N/A
- Revenue
- GRX N/A
- IFRX $187,930.00
- Revenue This Year
- GRX N/A
- IFRX $396.02
- Revenue Next Year
- GRX N/A
- IFRX $155.22
- P/E Ratio
- GRX $38.50
- IFRX N/A
- Revenue Growth
- GRX N/A
- IFRX 177.12
- 52 Week Low
- GRX $7.73
- IFRX $1.14
- 52 Week High
- GRX $10.40
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- GRX 40.84
- IFRX 24.46
- Support Level
- GRX $9.92
- IFRX $1.76
- Resistance Level
- GRX $10.23
- IFRX $1.34
- Average True Range (ATR)
- GRX 0.13
- IFRX 0.14
- MACD
- GRX -0.01
- IFRX -0.01
- Stochastic Oscillator
- GRX 10.53
- IFRX 1.39
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.